Rifaximin is a semi-synthetic, nonsystemic antibiotic. It is indicated and FDA approved (2004) for the treatment of travelers' diarrhoea and Small Intestine Bacterial Overgrowth (SIBO).

Clinical info (page1)

Clinical info (page2)

Click here to download the Orphan (Special Access Scheme)
drug order and payment form.

Click here for the TGA Special Access Scheme (SAS) Proforma
(One Proforma must be completed for each therapeutic
agent you wish to prescribe to your patient)